文献速递病毒性肝炎

柬埔寨无免疫球蛋白策略预防乙肝病毒母婴传播(TA-PROHM):单臂、多中心、4期试验

Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.
PubMed 文献 · Lancet Infect Dis · 2022-05-25

TA-PROHM是一项在柬埔寨五家产科单位开展的单臂、多中心、4期试验,评估基于HBeAg快速诊断和ALT算法判断替诺福韦资格的无乙肝免疫球蛋白策略预防HBV母婴传播的效果。共筛查21251名孕妇,入组1194名HBsAg阳性孕妇,其中338名符合替诺福韦条件。替诺福韦符合组317名婴儿中4名(1% [95% CI 0.34-3.20])在6月龄时感染HBV;未接受HBIg的271名婴儿中4名(1% [0.40-3.74])感染。未接受HBIg时,产前接受替诺福韦超过4周的227名妇女所生婴儿中0名(0% [0-1.61])发生母婴传播,而接受替诺福韦不足4周的36名妇女所生婴儿中3名(8% [1.75-22.47])发生传播。

要点

  • 无HBIg策略下,替诺福韦符合组317名婴儿6月龄HBV感染率为1%(95% CI 0.34-3.20)。
  • 未接受HBIg时,产前替诺福韦超过4周者婴儿感染0%(0/227),不足4周者8%(3/36)。
  • 替诺福韦不符合组712名婴儿6月龄HBV感染率为1%(95% CI 0.40-2.02)。

核心结论

  • 使用HBeAg快速诊断和基于ALT的算法评估替诺福韦资格的无免疫球蛋白策略,在产前至少4周开始替诺福韦时能有效预防HBV母婴传播。

研究设计与样本

  • TA-PROHM为在柬埔寨五家产科单位开展的单臂、多中心、4期试验,注册号NCT02937779。
  • 纳入18岁及以上HBsAg阳性孕妇,排除HCV或HIV阳性、肌酐清除率低于30 mL/min、严重妊娠疾病及计划在研究点外分娩者。
  • 2017年10月4日至2019年1月9日,HBeAg快速诊断阳性孕妇符合替诺福韦条件;2019年1月9日起,HBeAg阴性且ALT≥40 IU/L的孕妇也符合条件。
  • 符合条件组口服替诺福韦二吡呋酯300 mg每日一次,从妊娠第24周至产后6周。
  • 主要结局为6月龄婴儿HBsAg阳性且经HBV DNA定量确认的比例,采用改良意向治疗分析,排除失访或6月龄前退出者。

主要发现

  • 2017年10月4日至2020年11月27日筛查21251名孕妇,HBsAg阳性1194名(6%)入组,其中338名(28%)符合替诺福韦条件。
  • 替诺福韦符合组317名婴儿中4名(1% [95% CI 0.34-3.20])6月龄时感染HBV;未接受HBIg的271名婴儿中4名(1% [0.40-3.74])感染。
  • 未接受HBIg时,产前替诺福韦超过4周的227名妇女所生婴儿中0名(0% [0-1.61])发生母婴传播,不足4周的36名妇女所生婴儿中3名(8% [1.75-22.47])发生传播。
  • 替诺福韦不符合组712名婴儿中7名(1% [95% CI 0.40-2.02])6月龄时感染HBV;未接受HBIg的567名婴儿中6名(1% [0.39-2.30])感染。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV) is based on administration of vaccine and immunoglobulins (HBIg) to newborns at birth and maternal antiviral prophylaxis for those with an HBV-DNA viral load of at 5·3 log10 IU/mL or more. Many low-income and middle-income countries face difficulty in accessing HBIg and HBV-DNA quantification. The aim of this study was to evaluate the effectiveness of an HBIg-free strategy to prevent MTCT of HBV. METHODS: TA-PROHM was a single-arm, multicentre, phase 4 trial done in five maternity units in Cambodia. Pregnant women who were positive for hepatitis B surface antigen (HBsAg), aged 18 years or older were included. Women who were HCV or HIV positive, had creatinine clearance of less than 30 mL/min, severe gravid disease, and planned to give birth outside the study sites were excluded. From Oct 4, 2017, to Jan 9, 2019, HBsAg positive pregnant women who tested positive for hepatitis B e antigen (HBeAg) with a rapid diagnostic test were eligible to receive tenofovir disoproxil fumarate. From Jan 9, 2019, women who were HBeAg negative with an alanine aminotransferase concentration of ≥40 IU/L were also eligible to receive tenofovir disoproxil fumarate. Women in the tenofovir disoproxil fumarate eligible group received 300 mg of tenofovir disoproxil fumarate orally once a day from the 24th week of gestation until 6 weeks postpartum. The primary outcome was the overall proportion of infants who were HBsAg positive at 6 months of life, confirmed by positive HBV DNA quantification. For the primary outcome, the proportion (95% CI) of infants with HBsAg at 6 months was stratified according to infant's HBIg status, duration of maternal tenofovir disoproxil fumarate treatment (>4 weeks and ≤4 weeks), and study period (before and after the change in therapeutic algorithm) and was measured in a modified intention-to-treat analysis, which excluded infants lost to follow-up or who were withdrawn before 6 months. The study is registered with ClinicalTrials.gov, NCT02937779. FINDINGS: From Oct 4, 2017, to Nov 27, 2020, 21 251 pregnant women were screened for HBsAg, of whom 1194 (6%) were enrolled in the study: 338 (28%) were eligible to receive tenofovir disoproxil fumarate. For the tenofovir disoproxil fumarate eligible group, four (1% [95% CI 0·34-3·20]) of 317 infants had HBV infection at 6 months; in the subgroup of 271 children who did not receive HBIg, four (1% [0·40-3·74]) had HBV infection at 6 months. In absence of HBIg, MTCT HBV transmission occurred in none (0% [0-1·61]) of 227 women who received tenofovir disoproxil fumarate for more than 4 weeks before giving birth and three (8% [1·75-22·47]) of 36 women who received tenofovir disoproxil fumarate for less than 4 weeks. In the tenofovir disoproxil fumarate ineligible group, seven (1% [0·40-2·02]) of 712 infants had HBV infection at 6 months; in the subgroup of 567 children who did not receive HBIg, six (1% [0·39-2·30]) had HBV infection at 6 months. INTERPRETATION: An immunoglobulin-free strategy using an HBeAg rapid diagnosis test and alanine aminotransferase-based algorithm to assess eligibility for tenofovir, is effective at preventing MTCT of HBV when tenofovir was initiated at least 4 weeks before birth. FUNDING: French Agency for Research on AIDS and Viral Hepatitis and Emerging Infectious diseases. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Segeral O, Dim B, Durier C, et al. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial. Lancet Infect Dis. 2022. PMID: 35643089. doi:10.1016/S1473-3099(22)00206-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。